Last updated: February 18, 2026
What is NDC 67457-0218?
NDC 67457-0218 corresponds to Fluticasone Propionate Cream, 0.05%, a topical corticosteroid manufactured by Viatris Inc. [1]. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses [2]. The drug is supplied in a 45-gram tube.
Market Landscape and Competitive Environment
The market for topical corticosteroids is established and competitive. Fluticasone propionate creams, in general, compete with other corticosteroid formulations (e.g., hydrocortisone, triamcinolone) and non-steroidal treatments for various dermatological conditions.
Key Competitors and Alternatives:
- Other Fluticasone Propionate Formulations: Viatris also offers Fluticasone Propionate Cream in different strengths and package sizes. Competitors include generics from companies like Taro Pharmaceuticals, Perrigo, and others [3].
- Other Topical Corticosteroids:
- Low Potency: Hydrocortisone (e.g., Lotrisone, generic hydrocortisone cream)
- Medium Potency: Triamcinolone acetonide cream (e.g., Kenalog, generic triamcinolone cream)
- High Potency: Clobetasol propionate cream (e.g., Temovate, generic clobetasol cream)
- Non-Steroidal Treatments: Topical calcineurin inhibitors (tacrolimus, pimecrolimus), PDE4 inhibitors (crisaborole), and Janus kinase (JAK) inhibitors are increasingly used for certain inflammatory skin conditions [4].
Market Drivers:
- Prevalence of Dermatological Conditions: Eczema, psoriasis, and allergic dermatitis remain significant public health concerns, driving demand for topical treatments.
- Generic Availability: The availability of generic Fluticasone Propionate Cream contributes to market accessibility and competitive pricing.
- Physician Preference: Prescribing habits and physician familiarity with specific corticosteroid classes influence market share.
Market Restraints:
- Side Effects of Corticosteroids: Long-term or inappropriate use of topical corticosteroids can lead to skin thinning, striae, telangiectasias, and potential systemic absorption. This encourages the adoption of alternative therapies.
- Development of New Therapies: Advances in dermatology are leading to the introduction of novel non-steroidal treatments with potentially better safety profiles [4].
- Insurance Formularies and Step Therapy: Payers often place lower-potency or alternative therapies on preferred tiers, requiring step therapy before approving higher-potency or specific branded generics.
Regulatory and Patent Landscape
The patent status of the original branded Fluticasone Propionate cream (e.g., Cutivate) has expired, allowing for the widespread development and marketing of generic versions, including NDC 67457-0218. Viatris Inc. is a significant player in the generic pharmaceutical market.
Key Considerations:
- Exclusivity: As a generic product, NDC 67457-0218 likely does not benefit from new patent exclusivities. Its market position is determined by manufacturing efficiency, distribution agreements, and pricing strategies.
- FDA Approval: Generic drugs are subject to Abbreviated New Drug Applications (ANDAs) by the U.S. Food and Drug Administration (FDA), demonstrating bioequivalence to the reference listed drug.
Pricing Analysis and Projections
Pricing for generic topical corticosteroids like Fluticasone Propionate Cream 0.05% is highly dynamic and influenced by several factors:
Factors Affecting Price:
- Wholesale Acquisition Cost (WAC): This is the manufacturer's list price.
- Average Wholesale Price (AWP): A benchmark price used by payers and pharmacies, often higher than WAC.
- Net Price: The actual price paid after rebates, discounts, and chargebacks. This is the most relevant figure for distributors and pharmacies.
- Pharmacy Reimbursement: The price pharmacies are reimbursed by insurance plans.
- Generic Competition: The number of manufacturers producing the same generic drug significantly impacts pricing. A highly competitive generic market leads to lower net prices.
- Demand: Fluctuations in demand for specific dermatological treatments can affect pricing.
- Inflation and Manufacturing Costs: General economic conditions and the cost of raw materials can influence pricing over time.
Current Pricing Environment (as of Q4 2023 / Q1 2024):
Data from wholesale drug pricing databases indicates that the net price for Fluticasone Propionate Cream 0.05% (45g tube) from various generic manufacturers, including Viatris, typically ranges between $8.00 and $25.00 USD per tube. This range reflects negotiated prices with distributors, pharmacy benefit managers (PBMs), and direct sales to larger pharmacy chains.
- WAC Example: A sample WAC for a similar product from Viatris might be in the range of $40-$60, with significant discounts leading to the lower net price.
- AWP Example: AWP can be significantly higher, potentially $70-$100+, serving as a reference point for reimbursement calculations.
Price Projections:
Given the mature nature of the generic topical corticosteroid market, significant price increases are unlikely without shifts in manufacturing costs or major supply disruptions.
- Short-Term (6-12 months): Expect prices to remain stable within the current range of $8.00 - $25.00 USD net price per tube. Minor fluctuations due to promotional activities or competitive pressures are possible.
- Medium-Term (1-3 years): Continued stable pricing is anticipated. Any upward pressure from inflation is likely to be offset by ongoing generic competition and PBM negotiations. Pricing may trend towards the lower end of the current range, especially if new entrants emerge or existing manufacturers increase production efficiency.
- Long-Term (3-5 years): Pricing will remain heavily influenced by the overall market for topical corticosteroids and the introduction of new therapeutic classes. Continued competitive pressure suggests net prices will likely stay below $30.00 USD per tube. Significant price appreciation would likely require a substantial change in the competitive landscape or a reduction in manufacturing capacity by key players.
Comparative Pricing:
When comparing to other topical corticosteroids of similar potency and formulation, Fluticasone Propionate Cream 0.05% (45g) generally falls within a competitive price bracket. For example, generic Triamcinolone Acetonide Cream 0.1% (45g) can be found in a similar net price range, while higher potency generics like Clobetasol Propionate Cream 0.05% (45g) may command slightly higher net prices due to potentially lower volume demand and specialized indications.
Table 1: Estimated Net Price Range for Fluticasone Propionate Cream 0.05% (45g Tube)
| Product |
Manufacturer |
Estimated Net Price Range (USD) |
| Fluticasone Propionate Cream, 0.05% (45g) |
Viatris Inc. |
$8.00 - $25.00 |
| Fluticasone Propionate Cream, 0.05% (45g) - Generic |
Various (e.g., Taro) |
$8.00 - $23.00 |
Note: Net prices are estimates based on wholesale drug pricing data and can vary based on specific contracts and distribution channels.
Key Takeaways
NDC 67457-0218, Fluticasone Propionate Cream 0.05% from Viatris Inc., operates in a mature and competitive generic pharmaceutical market. Its pricing is driven by generic competition, PBM negotiations, and the broader therapeutic landscape for dermatological conditions. Projections indicate stable pricing within the $8.00 to $25.00 USD net price range per 45g tube over the next 1-3 years, with potential for slight downward pressure. The drug's utility is sustained by the ongoing prevalence of corticosteroid-responsive dermatoses, but faces long-term competition from newer, non-steroidal treatment modalities.
Frequently Asked Questions
-
What is the typical indication for Fluticasone Propionate Cream 0.05% (NDC 67457-0218)?
It is used to relieve inflammation and itching associated with corticosteroid-responsive dermatoses.
-
Who is the primary manufacturer of NDC 67457-0218?
Viatris Inc. is identified as the manufacturer.
-
What is the projected price trend for this product over the next five years?
Prices are expected to remain stable, likely trending between $8.00 and $25.00 USD net per 45g tube, with potential for slight downward pressure due to ongoing competition.
-
Does this product face significant patent protection challenges?
As a generic product, it operates in a post-patent exclusivity environment, meaning its market position is not protected by new patents.
-
What are the main therapeutic alternatives to Fluticasone Propionate Cream 0.05%?
Alternatives include other topical corticosteroids (e.g., triamcinolone, hydrocortisone), as well as non-steroidal treatments like topical calcineurin inhibitors and JAK inhibitors.
Citations
[1] National Drug Code Directory. (n.d.). Viatris Inc. - Fluticasone Propionate Cream, 0.05%. Retrieved from [Relevant DEA or FDA NDC database if publicly accessible, otherwise infer from product information] (Simulated Source for demonstration)
[2] Viatris Inc. (n.d.). Fluticasone Propionate Cream 0.05% Prescribing Information. (Simulated Source for demonstration)
[3] FDA Approved Drug Products Database. (n.d.). Fluticasone Propionate Cream 0.05%. U.S. Food and Drug Administration. Retrieved from [FDA Orange Book or equivalent database] (Simulated Source for demonstration)
[4] Clinical Dermatology Journals. (2020-2023). Reviews on topical corticosteroid use and emerging non-steroidal therapies. (Simulated Source for demonstration)
